ArticleViruses2026
Functional Evaluation of Neutralizing Antibodies Against Foot-and-Mouth Disease Virus Serotype O Using a Luciferase-Based Surrogate Neutralization Assay.
Article in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Foot-and-mouth disease (FMD) is a highly contagious viral disease that seriously threatens livestock health. Protective immunity induced by vaccination is primarily associated with the generation of neutralizing antibodies; however, conventional virus neutralization tests are time-consuming and require the handling of live virus, limiting their suitability for rapid and repeated evaluation in routine settings. In this study, we established a surrogate neutralization assay for the functional evaluation of neutralizing antibody activity against FMD virus (FMDV) serotype O. The assay measures changes in luciferase-based luminescent signals generated following exposure of LgBiT-expressing cells to HiBiT-tagged virus-like particle (VLP) preparations. FMDV serotype O-derived VLPs exhibited stable capsid protein expression, assembly characteristics, and morphological integrity similar to those of virus particles, as confirmed by sucrose gradient fractionation and electron microscopy. In the presence of neutralizing antibodies, a reduction in luminescent signals was observed, enabling functional discrimination of antibody activity. The surrogate assay results showed a strong correlation with those of the conventional virus neutralization test for FMDV serotype O (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.